Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of LPM6690176 Capsules in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
Latest Information Update: 11 Feb 2026
At a glance
- Drugs LPM 6690176 (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Luye Pharma Group
Most Recent Events
- 11 Feb 2026 New trial record